Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Expert Review of Precision Medicine and Drug Development|February 12, 2019
TRAIL pathway targeting therapeuticsMarie D Ralff, Wafik S El-DeiryTranslational Cancer Research|September 4, 2018
ONC201: a new treatment option being tested clinically for recurrent glioblastomaMarie D Ralff, Amriti R Lulla, Jessica Wagner, et al.American Journal of Cancer Research|February 10, 2022
miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cellsAmriti R Lulla, Yan Zhou, Marie D Ralff, et al.Cancer Biology & Therapy|October 26, 2021
Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivoJocelyn E Ray, Marie D Ralff, Aakash Jhaveri, et al.Molecular Cancer Research : MCR|March 29, 2018
ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate CancerAvital Lev, Amriti R Lulla, Brian C Ross, et al.Oncotarget|November 4, 2020
TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptoticMarie D Ralff, Aakash Jhaveri, Jocelyn E Ray, et al.Molecular Cancer Therapeutics|April 21, 2017
ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent MechanismsMarie D Ralff, Christina L B Kline, Ozan C Küçükkase, et al.Neoplasia (New York, N.Y.)|December 8, 2017
Role of Dopamine Receptors in the Anticancer Activity of ONC201Christina Leah B Kline, Marie D Ralff, Amriti R Lulla, et al.Cancer Biology & Therapy|December 3, 2021
Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivoAakash V Jhaveri, Lanlan Zhou, Marie D Ralff, et al.Oncotarget|November 16, 2017
Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIPAvital Lev, Amriti R Lulla, Jessica Wagner, et al.Pageof 2